IMP has worked with ERN EURO‑NMD and several leading patient organisations, including Mitocon, the Bulgarian Association for Neuromuscular Diseases, and […]...

UMDF, in collaboration with UCB, has launched a new resource designed specifically for people living with TK2d and those who […]...

This year UCB is collaborating with the global Mitochondrial disease community to collect works of art (painting, poetry, photography, sculpture, […]...

Five years ago, a research project began that is now influencing  anesthetic practice worldwide. It all started when Dr. Yaremy […]...

First Patient Dosed in Phase 3 KHENERFIN Study of Sonlicromanol for m.3243A>G Primary Mitochondrial Disease Khondrion has announced a major […]...

We are delighted to announce that three additional mitochondrial organisations have joined IMP, further strengthening our global network and amplifying […]...

European Commission approves KYGEVVI® for TK2d IMP warmly welcomes the decision by the European Commission to approve KYGEVVI® (doxecitine and doxribtimine) as […]...

Announcing IMP’s New Scientific and Medical Advisory Committee IMP is delighted to introduce our new Scientific and Medical Advisory Committee, a […]...

New MELAS Consensus: A Critical Resource for Doctors and Patients Worldwide In November 2025, leading international experts gathered in Pisa, […]...

MitMED – Building a European Centre of Excellence in Mitochondrial Medicine Mitochondria are central regulators of cellular life, integrating metabolism, […]...

Growing Recognition of the Patient Voice in Research A meaningful shift is taking place in the rare disease research landscape: […]...

Inside the Mito Town Hall: Insights That Matter The Mito Town Hall meetings have become an important annual touchpoint for […]...

The Mitochondrial Disease Conference 2026, hosted by Mitocon on 23–24 January in Pisa, brought together clinicians, researchers, patients, and industry partners for […]...

Setback for LHON Treatment in the US: IMP Supports Urgent Patient Need International Mito Patients (IMP), the global federation representing patient […]...

Strengthening Europe’s Rare Epilepsy Voice Through the E+ Alliance The E+ Alliance presentation outlines a fast‑growing European network dedicated to […]...

EMA grants positive CHMP opinion for Kygevvi® for Treatment of TK2d International Mito Patients (IMP) and the global mitochondrial disease community […]...

Funding for the SynLeigh Project to Advance New Therapies for Leigh Syndrome IMP, Mitocon and Cure Mito Welcome ERDERA Funding International […]...

IMP Annual Meeting 30-31 May 2026, France IMP’s Annual Meeting will take place 30–31 May 2026 at Brit Hotel Acropole, […]...

Patients at the Heart of Research: IMP’s Role in the SIMPATHIC Drug Repurposing Project The SIMPATHIC project continues to make […]...

Rare Disease Day 28 Feb 2026 Rare Disease Day is a global campaign that highlights the 300 million people worldwide […]...